ijms-logo

Journal Browser

Journal Browser

Skin Cancer: A Focus from Pathophysiology to Novel Therapeutic Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 2428

Editor


E-Mail Website
Guest Editor
Department of Dermatology, National Institute of Medicine of the Ministry of the Interior and Administration, 02-507 Warsaw, Poland
Interests: skin cancer; melanoma; keratinocyte carcinoma; pathophysiology; biomarkers; immunotherapy; targeted therapy; nanomedicine; resistance; precision oncology

Special Issue Information

Dear Colleagues,

Skin cancers—from actinic‑keratosis-derived squamous cell carcinoma to aggressive metastatic melanoma—are the most common human malignancies and an escalating global burden. Although breakthroughs in genomics, imaging, and immuno‑oncology have reshaped our understanding of cutaneous tumorigenesis, many patients still face delayed diagnoses, therapeutic resistance, and treatment‑limiting toxicities. Deeper insight into disease mechanisms and genuinely innovative interventions are urgently required.

This Special Issue, “Skin Cancer: A Focus from Pathophysiology to Novel Therapeutic Strategies” invites original research papers, short communications, and in‑depth reviews that illuminate the biology of skin cancer and translate discovery into improved care. Topics of interest include (i) genomic, epigenomic, and metabolic drivers of malignant transformation; (ii) tumour–stromal–immune crosstalk, microenvironmental dynamics, and the cutaneous microbiome; (iii) emerging biomarkers, liquid biopsies, and advanced imaging for early detection, prognosis, and real‑time therapeutic monitoring; (iv) AI‑assisted predictive modelling and drug discovery pipelines; (v) next‑generation treatments—signal pathway inhibitors, immune checkpoint modulators, adoptive cell therapy, oncolytic viruses, CRISPR‑based platforms, vaccines, photodynamic/photothermal approaches, and nanomedicine‑enabled combinations; (vi) mechanisms of resistance and toxicity mitigation; and (vii) population studies, real‑world evidence, and survivorship quality‑of‑life assessments.

We particularly encourage submissions that bridge fundamental science and clinical practice, present first‑in‑class therapeutic concepts, or showcase interdisciplinary collaborations. By assembling diverse perspectives, this Special Issue seeks to provide a comprehensive snapshot of current progress and to accelerate precision prevention and durable control of skin cancer.

We look forward to receiving your valuable contributions and advancing the fight against skin cancer together.

Dr. Piotr Sobolewski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin cancer
  • melanoma
  • keratinocyte carcinoma
  • pathophysiology
  • biomarkers
  • immunotherapy
  • targeted therapy
  • nanomedicine
  • resistance
  • precision oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

25 pages, 2548 KB  
Article
Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells
by Radosław Wolan, Joanna Wawszczyk, Arkadiusz Orchel and Małgorzata Kapral
Int. J. Mol. Sci. 2025, 26(23), 11403; https://doi.org/10.3390/ijms262311403 - 25 Nov 2025
Cited by 1 | Viewed by 751
Abstract
Malignant melanoma is skin cancer with high metastatic potential and resistance to treatment. Significant progress has been made following the introduction of its treatment kinase inhibitors such as binimetinib. Some studies suggested that the combination of metformin with BRAF/MEK inhibitors suppresses cancer cell [...] Read more.
Malignant melanoma is skin cancer with high metastatic potential and resistance to treatment. Significant progress has been made following the introduction of its treatment kinase inhibitors such as binimetinib. Some studies suggested that the combination of metformin with BRAF/MEK inhibitors suppresses cancer cell growth and progression. This study aimed to assess the impact of metformin and binimetinib, both individually and in combination, on the growth, proliferation, and apoptosis of melanoma cells in vitro. The study also sought to predict potential interactions between metformin and binimetinib when co-administered employing in silico analysis. Cell growth and proliferation of melanoma cells exposed to metformin and binimetinib, alone and in combination, were determined by SRB and BRDU assays. Further investigations were performed using real-time RT-qPCR and ELISA method. These results revealed that the simultaneous use of metformin and binimetinib exerted an additive or synergistic inhibitory effect on melanoma cell growth. The concomitant effect of both compounds depended on the concentrations used and was caused by the reduced proliferation and/or increased apoptosis of melanoma cancer cells. In conclusion, the combination of metformin and binimetinib may have potential anticancer effects on melanoma cells; however, more studies are needed to elucidate the exact mechanisms of their combined action. Full article
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 528 KB  
Review
Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review
by Piotr Sobolewski, Mateusz Koper, Anna Wasaznik-Jedras, Malgorzata Kolos and Irena Walecka
Int. J. Mol. Sci. 2026, 27(3), 1520; https://doi.org/10.3390/ijms27031520 - 4 Feb 2026
Cited by 1 | Viewed by 1034
Abstract
Cellular senescence is a stress-induced cell-cycle arrest that constrains expansion of ultraviolet-damaged keratinocytes yet can remodel the microenvironment. This systematic review evaluated histological and genetic or epigenetic senescence markers in actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and basal cell carcinoma (BCC). [...] Read more.
Cellular senescence is a stress-induced cell-cycle arrest that constrains expansion of ultraviolet-damaged keratinocytes yet can remodel the microenvironment. This systematic review evaluated histological and genetic or epigenetic senescence markers in actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and basal cell carcinoma (BCC). PubMed, Scopus, and Web of Science were searched (January 2005–May 2025); 34 human studies were included. AK showed an early senescent signature with frequent cyclin-dependent kinase inhibitor p21 (p21CIP1) expression (82.1%) and DNA damage signaling, including phosphorylated histone H2AX (gamma-H2AX) positivity (77%). In invasive cSCC, p21CIP1 fell to 43.9% and tumor suppressor p53 immunoreactivity often declined, whereas cyclin-dependent kinase inhibitor p16 (p16INK4a) commonly accumulated without arrest, including cytoplasmic staining at invasion fronts. Reported escape pathways involved c-Jun N-terminal kinase 2 activity and long noncoding RNA PVT1–dependent repression of p21. Telomerase reverse transcriptase (TERT) promoter mutations were prevalent in cSCC (about 50%) and BCC (up to 78%) but uncommon in AK, consistent with late telomerase activation. Study heterogeneity, variable antibody scoring, and limited assessment of senescence-associated beta-galactosidase and secretory mediators restricted cross-study comparability. Standardized, spatially resolved profiling may refine risk stratification and support senescence-targeted prevention and therapy in keratinocyte cancers. Full article
Show Figures

Figure 1

Back to TopTop